Abstract: Disclosed herein is a non-transitory computer-readable media having computer-executable instructions thereon. When executed by the processor of a mobile computing device, the computer-executable instructions cause the processor to wirelessly communicatively couple the mobile computing device to a GI sensor (optionally by displaying instructions on a pairing screen), display a sensor placement screen that instructs the user to place the GI sensor on a body of a patient, prompts the user to administer a GI agent into the body of the patient; transmit a signal from the mobile computing device to the GI sensor to cause the GI sensor to initiate collection of light absorbance data for calculating GI function of the patient; receive light absorbance data from the GI sensor, and store the received light absorbance data.

Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Abstract: A method for determining a glomerular filtration rate (GFR) in a patient includes administering to said patient a compound of Formula I and transdermally measuring spectral energy emitted by the compound of Formula I over a measurement time window. The spectral energy is emitted by the compound of Formula I in response to electromagnetic radiation delivered to the compound of Formula I. The method also includes determining the GFR in said patient based on the measured spectral energy emitted by the compound of Formula I over the measurement time window by fitting an exponential function to the spectral energy as a function of time or a linear function to the log of the spectral energy as a function of time to calculate a rate constant associated with renal clearance over the measurement time window and directly related to the GFR normalized to a body size metric of the patient.

Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Abstract: The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease state, and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered. Establishing the baseline may include enterally administering a first dosage of a composition comprising a fluorescent tracer, measuring a first amount of the administered dose that can be found outside the gut over a period of time, and determining a baseline total percentage of the administered dose recovered.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.

Abstract: The present disclosure relates to methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method comprises administering, subcutaneously or intramuscularly, a pyrazine compound of Formula I to a patient, wherein the administration produces a plasma concentration of the compound that is substantially similar to a plasma concentration produced by intravenous administration of an identical amount of the compound; and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which may be detected using one or more sensors. The rate in which the fluorescence decreases in the patient may be used to calculate the renal glomerular filtration rate in the patient.

Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 formulas I and II may be characterized as electron withdrawing groups, white Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: Disclosed herein is a non-transitory computer-readable media having computer-executable instructions thereon. When executed by the processor of a mobile computing device, the computer-executable instructions cause the processor to wirelessly communicatively couple the mobile computing device to a GI sensor (optionally by displaying instructions on a pairing screen), display a sensor placement screen that instructs the user to place the GI sensor on a body of a patient, prompts the user to administer a GI agent into the body of the patient; transmit a signal from the mobile computing device to the GI sensor to cause the GI sensor to initiate collection of light absorbance data for calculating GI function of the patient; receive light absorbance data from the GI sensor, and store the received light absorbance data.

Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.

Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.

Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.